ACRV

Acrivon Therapeutics, Inc. Common Stock (ACRV) SWOT Analysis Analysis (2026)

Invetso Score: 3.8/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 4.2 (Moderate)

High current and quick ratios indicate ample near-term liquidity versus peers, reducing refinancing pressure despite weaker operating efficiency.

Very low debt-to-equity suggests a lightly levered balance sheet versus more indebted peers, which can preserve financial flexibility through volatility.

Weaknesses

Score:

Negative ROIC indicates capital is not yet earning its cost, leaving ACRV structurally behind profitable peers on value creation.

A 595-day cash conversion cycle signals severe working-capital drag versus peers, tying up cash and limiting operating efficiency.

Net debt to EBITDA remains positive despite minimal leverage, implying earnings capacity is still insufficient relative to peers to absorb obligations comfortably.

Opportunities

Score:

If working-capital discipline improves, the unusually long cash conversion cycle could release cash faster than peers and strengthen operating flexibility.

Balance-sheet liquidity provides room to fund commercialization or pipeline execution versus tighter peers, supporting longer-duration strategic optionality.

Low leverage gives ACRV more capacity than peers to absorb near-term investment or restructuring needs without immediate balance-sheet stress.

Threats

Score:

Persistent negative ROIC versus profitable peers raises the risk that capital deployment continues to destroy value and depress competitive positioning.

The extreme cash conversion cycle increases dependence on external funding relative to peers, making execution delays more damaging to liquidity.

If operating losses persist, even a liquid balance sheet can erode quickly versus peers with stronger earnings and cash generation.

Overall Score

Score:

ACRV’s peer positioning is weakened by negative capital returns and severe working-capital inefficiency, while liquidity and low leverage only partially offset the structural gap.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Acrivon Therapeutics, Inc. Common Stock. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →